Advertisement
Home »

Both NICHE-2 & NICHE-3 Trials Show High Efficiency of Short Neoadjuvant Immunotherapy in dMMR Colon Cancer

Nov 11, 2024

REFERENCES & ADDITIONAL READING

  1. Chalabi M, et al. N Engl J Med. 2024;390:1949-1958.
  2. Chalabi M, et al. Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2. Abstract LBA24. ESMO Congress 2024, 13–17 September, Barcelona, Spain.
  3. De Gooyer P, et al. Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study. Abstract 503O. ESMO Congress 2024, 13–17 September, Barcelona, Spain.

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

RELEVANT ARTICLES FOR YOU

Advertisement